Purpose: Although symptoms are expected to improve after the resection of pituitary macroadenomas, tumor resection volume does not always correlate with the patient's symptoms. Our objectives were to assess the pre and postoperative volumes of pituitary macroadenomas before, immediately after surgery and at follow-up, and to explore possible associations and correlations among these changes and symptoms. Materials and methods: We retrospectively reviewed the clinical records and the preoperative and postoperative magnetic resonance imaging studies at 24 hours and at 3, 6 and 9 months follow-up of 146 patients who underwent surgery for pituitary macroadenomas. We measured tumor volumes before and after surgery and compared changes with symptom improvement. Results: The mean preoperative tumor volume was 24.66 cm 3 (standard deviation 65.18 cm 3 , 95% confidence interval (CI) 14-35.32). The most common symptoms were visual/cranial nerve abnormalities (65%) and headaches (56%). Immediately after surgery, symptoms persisted without significant changes in all patients. A progressive tumor volume decrease was noted during follow-up, and symptoms improved in 78% of patients. Despite no imaging evidence of chiasm or cavernous sinus compression, 32 patients showed no symptom improvement. Patients with symptoms for more than 1 year (mean duration of symptoms 26 months, SD 24.3, 95% CI 22.03-29.97 months) had a higher risk of the persistence of symptoms compared to patients with a mean duration of symptoms of less than 1 year (odds ratio 2.5, 95% CI 2.4-3, P < 0.005). Conclusions: The duration of symptoms prior of surgery is a more important factor than tumor resection volume alone when considering the long-term outcome of symptoms. Furthermore, lack of symptom improvement in the immediate postoperative period does not necessarily represent an inadequate resection.
Introduction
Pituitary adenomas are the most common tumors of the sellar region arising from pituitary epithelial cells. They account for 12-19% of intracranial tumors and are the third most common primary intracranial tumor in the adult after meningiomas and gliomas. 1, 2 Tumors that are 10 mm or larger are arbitrarily defined as macroadenomas, and those smaller than 10 mm are termed microadenomas. Microadenomas are found in 14% of post-mortem studies whereas macroadenomas are seen in only 0.6-1.5%. 3 A large number of microadenomas secrete an excess amount of hormone but most are clinically silent. Macroadenomas generally come to medical attention because of mass effect causing headache, 4 visual field deficits due to compression of the optic chiasm 5 or cranial nerve (CN) deficits (CN III, IV, VI and V1 and V2 branches of CN V) due to invasion of the cavernous sinuses. 6 Symptoms related to mass effect are present in up to 70% of patients, with non-functioning macroadenomas at the time of diagnosis, and therefore therapy is directed at decompression. For most patients, trans-sphenoidal resection is the preferred treatment, although transcranial resection remains an option in lesions judged to be inaccessible by the trans-sphenoidal route. 7 Both endoscopic and transcranial surgery are effective treatments, with previous studies showing high rates (>80%) of resection. 8 However, the effectiveness of surgery on mass effect has been debated, with authors showing improvement after endoscopic surgery in the majority of patients with visual deficits (70%), but with complete recovery in less than half of them. 9 Improvement of headaches after endoscopic resection has been observed in up to 70% of patients, although a significant percentage (7.5%) has worsening of the intensity and frequency of headaches. 4 Cranial nerve palsies have also been shown to improve significantly after endoscopic resection. 10 Based on previous publications, symptom improvement following the resection of macroadenomas is mostly related to the volume of resected tumor. 5, 8, 11, 12 These studies show correlation between tumor resection rates and good clinical outcomes in terms of visual symptoms, dizziness and headaches. Factors that limit tumor resection, namely preoperative tumor size and volume, tumor texture and cavernous sinus invasion, have been emphasized as possible markers of poor postoperative outcomes.
Results describing only partial clinical improvement following decompression are concordant with our own experience, in which the change in symptoms following surgery does not necessarily match the volume of resected tumor. In other words, mass effect alone does not seem to explain entirely the evolution of symptoms. The purpose of this study was to correlate the volume of resection in pituitary macroadenomas with symptom improvement in the immediate postoperative setting and at follow-up.
Materials and methods

Patient population
This study was approved by the institutional review board at our hospital; informed consent was waived. We performed an institutional search for consecutive patients who had been diagnosed with a pituitary macroadenoma and underwent trans-sphenoidal resection between January 2011 and September 2016. Inclusion criteria were as follows: patients (a) received trans-sphenoidal surgery for pituitary adenoma; (b) underwent preoperative imaging with pre and post-contrast magnetic resonance imaging (MRI), immediate postoperative imaging (24 hours after surgery) and at least one follow-up imaging study after 3, 6 and 9 months; (c) underwent regular follow-up in the neurosurgery and ophthalmology departments of University of North Carolina Hospitals; (d) underwent ophthalmological examination including best-corrected visual acuity and visual field testing; (e) underwent early endocrinological follow-up after the surgery with complete pituitary hormone testing. Exclusion criteria were: (a) adenomas with largest diameter smaller than 1 cm; (b) patients with prior history of surgery or medical treatment for pituitary adenoma and evidence of tumor recurrence.
Imaging studies
All MRI studies were performed using 1.5 T magnets with a standard head coils. Conventional pituitary protocol MRI included axial, sagittal and coronal T1-weighted (TR/TE 400/10 ms) and T2-weighted (TR/TE 5000/100 ms) images; field of view 250 mm 2 ; matrix size 210 Â 256; 4 mm slice thickness). T1-weighted images were obtained through the sella before and after intravenous administration of a single dose (0.2 mmol/kg) of gadobenate dimeglumine (Multihance; Bracco Diagnostics, Princeton, NJ, USA).
Image analysis
All images were blindly reviewed by two radiologists with 3 (CV) and 1 (VO) years of experience in neuroimaging interpretation, respectively. The size of macroadenomas was defined based on the length of the maximal diameter of the lesion as follows: small macroadenoma (>1 cm to 2 cm); large macroadenoma (>2 cm to 4 cm); and giant adenoma (>4 cm). Signs of chiasm compression and cavernous sinus extension were evaluated on preoperative images. Chiasm compression was documented when significant chiasm displacement and/or T2 signal hyperintensity in the chiasm and/or proximal optic radiations were observed on T2-weighted images. Invasion of the cavernous sinuses was based on the Knosp criteria and considered positive if grading was greater than 2. 13 Pituitary hemorrhage was assessed qualitatively on T1 pre-contrast images and T2-weighted images. Measurements were made with standard PACS tools on T1-weighted post-contrast images. The maximum infrachiasmatic craniocaudal dimension of the macroadenoma was measured on sagittal images and the maximum anterior-posterior and transverse diameters were measured on axial images before and after surgery.
Tumor volume was calculated using the ellipsoid formula: V ¼ 4/3(a*b*c) with a, b and c representing the maximal anterior-posterior, transverse, and craniocaudal dimensions of the macroadenoma, respectively. According to Davies et al. ellipsoid and perimeter methods of tumor volume estimation are strongly correlated in preoperative and regularly shaped tumors. 14 The measurement of macroadenomas and volume calculations were repeated 24 hours after surgery. Volume reduction was calculated as a percentage of resected volume relative to preoperative volume. Postsurgical bleeding was evaluated qualitatively by searching for heme products on T2-weighted and pre-contrast T1-weighted images. The same measurements were repeated for the follow-up studies performed at 3, 6 and 9 months after surgery.
Extent of tumor resection and clinical outcomes
All 146 patients were treated with endoscopic transsphenoidal resection. Outcome was evaluated as an improvement of symptoms as reported on the medical records immediately after surgery and during clinical follow-up (3, 6 and 9 months).
Tumor resection was expressed as a percentage of resected tumor volume and total preoperative volume. Tumor features such as size, gross suprasellar extension, shape, cavernous sinus invasion, Knosp grade 3 and adjacent osseous erosion were correlated with the extent of surgical resection.
Statistical analysis
For the inter-observer reproducibility analysis, we used the interclass correlation coefficient (ICC). Quantitative variables were described as means AE standard deviation (SD). Proportions were used for qualitative variables (expected frequency and prevalence). To establish associations between continuous variables we used Student's t test after proving normality of distribution, and for qualitative variables we used the chi-square test or Fisher's exact test. We calculated odd ratios to establish the risk of persistence of symptoms in different conditions. We considered a P value of less than 0.05 as significant.
Results
Patient demographics and clinical presentation
A total of 146 patients were included in the study (57 women, 89 men). The mean age at presentation was 53 years (SD 31, 95% confidence interval (CI) 47.93-58.07). The duration of symptoms prior to surgery ranged from 2 days to 5 years. A total of 145 patients had decreased visual acuity with unilateral or bilateral temporal visual field deficits. Bitemporal and mixed field defects were the most prevalent pattern (65/145, 45%, 95% CI 0.366-0.533) followed by non-specific (55/145, 38%, 95% CI 0.3-0.464), monocular (24/145, 17%, 95% CI 0.109-0.236) and homonymous defects (1/145, 0.07%, 95% CI 0-0.038).
Eighty-two subjects (82/146, 56%, 95% CI 0.477-0.644) had headache and dizziness at presentation and seven patients (7/146, 5%, 95% CI 0.019-0.096) had cranial nerve deficits (extraocular deficits or facial patients). A total of 107 subjects (107/146, 73%, 95% CI 0.653-0.803) had non-functional macroadenomas and 39 (39/146, 27%, 95% CI 0.197-0.347) had endocrine altering macroadenomas, 27 of which with hyperprolactinemia (27/39, 70%, 95% CI 0.524-0.830), five (5/39, 13%, 95% CI 0.043-0.274) had panhypopituitarism, four (4/39, 10%, 95% CI 0.029-0.242) had adrenal insufficiency, one (1/39, 2.6%, 95% CI 0.001-0.135) had Cushing syndrome, one (1/39, 2.6%, 95% CI 0.001-0.135) had central hypothyroidism and one (1/ 39, 2.6%, 95% CI 0.001-0.135) had hypogonadism (Table 1) .
Preoperative tumor features
On the preoperative studies 48% (70/146, 95% CI 0.396-0.564) of patients showed chiasma compression with cavernous sinus extension, 27% (39/146, 95% CI 0.197-0.347) had chiasm compression alone, 11% (16/ 146, 95% CI 0.064-0.172) showed cavernous sinus extension alone, 3% (4/146, 95% CI 0.008-0.069) had chiasm and fronto-basal brain compression and 11 subjects (11/146, 7.5%, 95% CI 0.038-0.131) showed no significant mass effect (Table 2) . Sixteen (11%, 95% CI 0.064-0.172) patients showed evidence of pituitary hemorrhage on preoperative studies, only one of which presented with cranial nerve palsy. The remaining six patients presenting with cranial nerve palsy showed high grade cavernous sinus invasion (Knosp >3) . Among the 146 patients, 29 had small macroadenomas, 100 had large macroadenomas and 17 had giant macroadenomas. The average preoperative tumor 3 ) macroadenomas (95% CI 11.6-38.4, P < 0.05). A lower volume resection rate was also observed in patients with significant invasion of the cavernous sinuses (Knosp grade equal to or more than 3, 95% CI 16.3-48.8, P < 0.05) and gross suprasellar extension with bilobed shaped tumors (95% CI 18.88-41.12, P < 0.05). On 24-hour postoperative images, persistent mass-like abnormalities were observed in the majority of patients (87%, 95% CI 0.815-0.924). There was no significant improvement in the patients' symptoms on early clinical evaluation 24 hours after surgery.
Follow-up postoperative findings
There was an excellent correlation between the interobserver measurements of postoperative volumes at 3, 6 and 9 months after surgery, as shown by the ICCs equal to 0.91 (95% CI 0.87-0.93), 0.9 (95% CI 0.89-0.914) and 0.93 (95% CI 0.883-0.957), respectively. Eighty-two per cent (120/146, 95% CI 0.75-0.88) of patients had an overall tumor resection rate of more than 75% 3 months after surgery and 30% (44/146, 95% CI 0.228-0.383) had complete tumor resection. Only 78% (114/146, 95% CI 0.705-0.845) of patients demonstrated significant improvement of symptoms at 3, 6 and 9 months after surgery. Patients with an overall resection rate of less than 75% immediately postoperatively, 58% (85/146, 95% CI 0.498-0.663) showed progressive mass reduction over the course of follow-up, with a mild (10-15%) to moderate (>15%) decrease in tumor volume. However, patients with a tumor resection rate of less than 75% (18% of all patients, 26/146, 95% CI 0.12-0.25) showed a significantly higher rate of persistent symptoms (38%, 10/26, 95% CI 0.202-0.594, P < 0.03 Fisher's exact test). Thirty-two patients (22% of total, 32/146, 95% CI 0.155-0.295) showed no symptom improvement on long-term follow-up despite no imaging evidence of mass effect or chiasm compression or tumor re-growth ( Figure 1 ). Of these 32 patients, 26 had an overall tumor resection rate of more than 75% and eight patients had a resection rate of less than 75%.
Patients with a resection rate of less than 75% had an increased risk of persistent symptoms compared to patients with a greater than 75% resection rate (odds ratio (OR) 1.7, 95% CI 1.5-3.8, P < 0.05). Ophthalmological evaluation confirmed that these patients had no significant clinical improvement in visual field deficits compared to the preoperative evaluation.
Patients with smaller visual field defects (monocular, non-specific, homonymous) did not have significantly better clinical improvements in visual field defects compared to patients with evidence of larger visual field defects (bitemporal and mixed defects) prior to surgery (P > 0.05, chi-square test).
Seventy-one per cent of patients with positive postoperative outcomes and improvement of symptoms had a mean duration of symptoms before treatment of less than 1 year (mean duration of 3 months, SD 1.67-2.33). Eighty-one per cent of patients with negative outcomes and persistent symptoms after treatment had an overall mean duration of symptoms of more than 1 year (mean duration 26 months, SD 24.3, 95% CI 22.03-29.97 months). Thus patients with a duration of symptoms of more than 1 year had a 2.5 higher risk of persistent symptoms (OR 2.5, 95% CI 2.4-3, P < 0.005) (Figure 2) . Patients with a duration of symptoms greater than 1 year had an increased risk of having a lesser tumor resection volume compared to patients whose duration of symptoms was less than 6 months (OR 11.4, 95% CI 8.5-15.1, P < 0.05). Patients with a mean duration of symptoms of more than 1 year did not have significantly larger tumor volumes compared to patients with a mean duration of symptoms of less than 1 year (95% CI 22.1-26.4, P > 0.005) (Figure 3) . We did not find any differences in pretreatment tumor volumes, type of symptoms at presentation, gender and age at presentation in patients with an improvement of symptoms compared to patients without an improvement of symptoms after surgery (chi-square test, P > 0.05).
Remission of hyperprolactinemia was achieved, surgically, in 16 patients with macroprolattinomas (60%, 16/27, 95% CI 0.30-0.78). Patients with preoperative hypopituitarism did not show any improvement of symptoms on early (24 hours) or late (3, 6, 9 months) follow-up. A 43% rate of hypopituitarism was instead found after surgery (63/146, 95% CI 0.35-0.516). We had only one case of adrenocorticotrophic hormonesecreting macroadenoma, which presented with panhypopituitarysm after surgery.
Discussion
Previous studies have shown a correlation between tumor resection rates and good clinical outcomes in terms of visual symptoms, dizziness and headaches. 5, 8, 11, 12 In this regard, authors have tried to define early imaging signs of residual tumor that may lead to prompt resection of residual disease and potentially better outcomes. Follow-up imaging performed at least 3 months after surgery is judged to be reliable in Figure 2 . A 60-year-old man presenting with blurry vision for 5 months. Preoperative coronal T2-weighted (a) and post-contrast T1-weighted (b) images demonstrate a large pituitary mass (arrow) compressing the optic chiasm and nerves which appear flattened (white arrowheads). T2-weighted (c) and post-contrast T1-weighted (d) images 24 hours after surgery show large reduction of mass effect with decompressed optic nerves (black arrowheads). The patient had persistent symptoms in the immediate postoperative period but showed significant clinical improvement 6 months later, at which time T2-weighted (e) and post-contrast T1-weighted (f) images demonstrated further decrease in intrasellar tissue. defining residual tumor as blood products and hemostatic material have had time to be reabsorbed. 15, 16 Interestingly, none of our patients showed a significant improvement of symptoms immediately after surgery, regardless of tumor resection volume. This finding is different to previous reports that claim an early improvement of symptoms in 89% of patients. 16 We do not know the source of such discrepancy, but there may be effects from variables that were not measured or accounted for, such as the preoperative duration of symptoms which was not described in that particular study. One potential explanation for the lack of immediate improvement in our cohort is the possibility that post-surgical blood products and hemostatic material may contribute temporarily to persistent mass effect. Their presence also makes immediate postoperative scans difficult to interpret and could obscure a potential relationship between true tumor residual and the persistence of symptoms. During follow-up, we observed progressive reabsorption of post-surgical materials and found a high rate of tumor resection 3 months after surgery, with improvement of symptoms in many patients. However, a significant number showed no symptom improvement at follow-up despite lack of significant mass effect or chiasm compression on imaging. The reason behind this is uncertain but one potential mechanism may involve nerve ischemia resulting from extrinsic compression and decreased blood flow. Ischemia is known to have an immediate effect on the transmission of action potentials, which is potentially reversible on decompression. However, persistent compression may lead to loss of oligodendrocytes followed by axonal loss and eventually irreversible degeneration of the nerve. 17, 18 Once this has occurred surgical decompression would be unlikely to result in symptom improvement. Tumor consistency may also play a role in the severity of compression. Most pituitary adenomas are soft and can be removed by aspiration and curettage, 19 but 5-15% have a firm consistency due to a higher stromal component. 7, 19, 20 We hypothesize that tumors with a firm consistency may have a steadier mass effect, which could eventually lead to permanent damage and persistence of symptoms despite surgery.
We found that patients with lower extents of tumor resection more frequently had persistent or worsening symptoms after surgery. This is in line with previous studies that have shown an increased risk of persistent symptoms at follow-up in patients with lower volumes of resected tumor. 5, 8 Curiously, a significant number of patients who had a high extent of tumor resection in our study also showed persistent symptoms, even when there was a progressive decrease in tumor volume over time. We did not find a significant correlation between the extent of visual field defects before surgery and improvement of symptoms after resection. Therefore, the severity of visual deficits does not seem to correlate with the outcome. Furthermore, we noticed that patients with a duration of symptoms of more than 1 year had an even higher risk of persistent symptoms. A few authors have reported similar results, for example Cohen et al. showed that postoperative visual outcomes in patients with macroadenomas were inversely correlated with patient age and were significantly better in patients with a shorter duration of symptoms. 21 In another study by Thotakura et al. visual outcome was significantly correlated with both the rate of resection and duration of symptoms. The authors also found that the preoperative diameters of the lesions correlated with the duration of symptoms. 12 Gondim et al. found that tumor size was not significantly associated with postoperative visual impairment; however, the preoperative visual deficits and time intervals between the initial visual symptoms and surgery were significantly associated with postoperative visual outcomes. 22 Wolf et al. 23 made a quantitative assessment of headache severity before and after endoscopic trans-sphenoidal surgery for pituitary adenomas and found that headaches significantly improved after endoscopic trans-sphenoidal surgery. However, it remains uncertain which factors determine who benefits from the intervention. Variables such as tumor volume, extra-sellar extension, and chiasmatic compression do not correlate with headache severity or predict response to surgery. 23 Cranial nerve palsies are less frequently associated with macroadenomas than visual symptoms or headaches and are mostly seen in association with tumor apoplexy, and therefore tend to present acutely. 24, 25 In our study, pituitary apoplexy was observed in only one patient, whereas cranial nerve palsies presenting in the remaining six patients were attributed to cavernous sinus invasion. Only a few studies have focused on cranial nerve symptoms of macroadenomas related to cavernous sinus invasion without evidence of apoplexy. In all of these, trans-sphenoidal tumor resection was the treatment of choice and good postoperative outcome was related to early intervention. 10, 26 Finally, we found that patients with a longer duration of symptoms had a greater than 10 times higher risk of having smaller tumor resection volumes compared to patients whose duration of symptoms was less than 6 months. Also, we did not find any statistically significant difference in preoperative tumor size in patients with a mean duration of symptoms of less than 1 year compared to patients with mean duration of symptoms of over 1 year. These findings have not previously been reported in the literature and lead us to speculate that the duration of symptoms prior to surgery may play a more important role than tumor resection volume in terms of clinical outcome at follow-up.
One potential limitation of this study that is inherent to its retrospective nature is that headaches, visual defects and cranial nerve palsies were not systematically quantified. Therefore, the description of symptoms remains subjective.
